BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37192837)

  • 21. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
    Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
    Khansa I; Wang D; Coriddi M; Tiwari P
    Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Solsky I; Chen J; Rebbeck TR
    Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.
    Martelli G; Barretta F; Vernieri C; Folli S; Pruneri G; Segattini S; Trapani A; Carolla C; Spatti G; Miceli R; Ferraris C
    JAMA Surg; 2023 Dec; 158(12):1275-1284. PubMed ID: 37792368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
    Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
    JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.
    Armon S; Miron-Shatz T; Mor P; Tomer A; Levy-Lahad E; Michaelson-Cohen R; Srebnik N
    Climacteric; 2023 Apr; 26(2):154-160. PubMed ID: 36866779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    Mejia-Gomez J; Gronwald J; Senter L; Karlan BY; Tung N; Wolfman W; Demsky R; Sun P; Narod SA; Kotsopoulos J;
    Menopause; 2020 Dec; 27(12):1396-1402. PubMed ID: 32796289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
    Birrer N; Chinchilla C; Del Carmen M; Dizon DS
    Am J Clin Oncol; 2018 Mar; 41(3):313-315. PubMed ID: 26840041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
    Breda AS; Blaakær J
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    Wang Y; Song Z; Zhang S; Wang X; Li P
    Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    Perri T; Farhadian Y; Friedman E; Korach J
    Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.